To further explore the effect of combined treatment of bortezomib and WEE1 inhibitor, we treated the T-ALL cell lines with bortezomib alone and combined with Adavosertib (AZD), a first-in-class selective WEE1 inhibitor. This evidence concerns the gene WEE1 and acute lymphoblastic leukemia.